Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|January 26, 2021
A streamlined whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19Daniel Geanon, Brian Lee, Edgar Gonzalez-Kozlova, et al.
Biorxiv : the Preprint Server for Biology|September 21, 2023
Understanding the heterogeneity of alloreactive natural killer cell function in kidney transplantationDan Fu Ruan, Miguel Fribourg, Yuko Yuki, et al.
Frontiers in Immunology|June 15, 2026
High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLCKyoo Hyun Kim, Mina Han, Geon Woo Park, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancerVladimir Roudko, Diane Marie Del Valle, Emir Radkevich, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|August 1, 2019
A Modified Injector and Sample Acquisition Protocol Can Improve Data Quality and Reduce Inter-Instrument Variability of the Helios Mass CytometerBrian H Lee, Geoffrey Kelly, Shermineh Bradford, et al.
Cancer Research Communications|June 27, 2024
Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin LymphomaEdgar Gonzalez-Kozlova, Hsin-Hui Huang, Opeyemi A Jagede, et al.
Blood|May 8, 2026
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapiesLucia Y Chen, Adolfo Aleman, Marta Larrayoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2026
Gemcitabine plus nivolumab with carboplatin or oxaliplatin in cisplatin-ineligible patients with metastatic urothelial carcinoma: a randomized phase II trialZiao Li, Sudeh Izadmehr, Jeannie Hoffman-Censits, et al.
Nature Medicine|October 2, 2023
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trialMatthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr, et al.
Cancer Research Communications|March 27, 2023
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq AnalysisLijun Yao, Reyka G Jayasinghe, Brian H Lee, et al.
Pageof 3